Genecast MinerVa PRIME is our proprietary multi-gene mutation detection reagent kit used in our NGS-based test from ctDNA extracted from liquid biopsy samples. The detection of gene variants in the liquid biopsy samples provided by patients is followed by selection of the most effective targeted therapy for the patient.

Genecast MinerVa PRIME utilizes whole-exome sequencing of tumor tissue to identify tumor-specific somatic mutations with customized patient-specific probes to detect ctDNA in plasma samples. This enables the assessment of MRD status, providing valuable clinical insights for therapy selection, treatment efficacy evaluation, and recurrence risk prediction.

This personalized MRD detection approach represents a significant technological advancement, offering superior detection sensitivity and innovative design compared to existing MRD solutions. By integrating ultra-deep whole-exome/targeted drug panel sequencing, through 100,000× patient-specific customized panels/high-evidence hotspot combination panel, Genecast MinerVa PRIME effectively detects MRD, tumor evolution, and the emergence of second primary malignancies in plasma samples. Genecast MinerVa PRIME addresses limitations inherent in conventional methods, such as insufficient sensitivity in tissue-based assays or the restricted number of loci tracked in plasma. It enhances the detection sensitivity of ctDNA even at low levels and reduces testing costs. Furthermore, it solves the challenge of balancing personalized tracking with broad-spectrum monitoring of tumor evolution and second primary cancer detection, which used to be mutually exclusive in standard MRD assays.

We obtained CE marking for Genecast MinerVa PRIME for solid tumors in March 2022.